Strong Response to SARS-CoV-2 Vaccine Additional Doses Among Patients With Inflammatory Bowel Diseases

Millie D Long; Kimberly N Weaver; Xian Zhang; Kelly Chun; Michael D Kappelman; PREVENT-COVID Study Group

doi:10.1016/j.cgh.2022.01.056

Strong Response to SARS-CoV-2 Vaccine Additional Doses Among Patients With Inflammatory Bowel Diseases

Clin Gastroenterol Hepatol. 2022 Aug;20(8):1881-1883.e1. doi: 10.1016/j.cgh.2022.01.056. Epub 2022 Feb 9.

Authors

Millie D Long¹, Kimberly N Weaver², Xian Zhang³, Kelly Chun⁴, Michael D Kappelman⁵; PREVENT-COVID Study Group

Collaborators

PREVENT-COVID Study Group:
R Watkins, J Adler, M C Dubinsky, A Kastl, A Bousvaros, J A Strople, R K Cross, P D R Higgins, R C Ungaro, M Bewtra, E Bellaguarda, F A Farraye, M E Boccieri, A Firestine, M Fernando, M Bastidas, M Zikry, X Dai, J Adler, M C Dubinsky, A Kastl, A Bousvaros, R K Cross, P D R Higgins, R C Ungaro, M Bewtra, E Bellaguarda, F A Farraye, M E Boccieri, A Firestine, M Fernando, M Bastidas, M Zikry, X Dai

Affiliations

¹ Division of Gastroenterology and Hepatology, Department of Medicine, Center for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. Electronic address: millie_long@med.unc.edu.
² Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
³ Division of Gastroenterology and Hepatology, Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
⁴ Esoterix Specialty Laboratory, LabCorp, Calabasas, California.
⁵ Center for Gastrointestinal Biology and Disease, Division of Gastroenterology and Hepatology, Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has disrupted health care and has resulted in high mortality rates.¹ Vaccination is an international priority to mitigate the risks of SARS-CoV-2. The initial trials for development of SARS-CoV-2 vaccines excluded individuals with immunocompromising conditions.².

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

COVID-19 Vaccines* / immunology
COVID-19* / prevention & control
Humans
Inflammatory Bowel Diseases*
SARS-CoV-2
Vaccination

Substances

COVID-19 Vaccines